This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ImmunoCellular Therapeutics Reports Third Quarter 2012 Financial Results

ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced third quarter results for the period ended September 30, 2012.

For the three months ended September 30, 2012, the Company reported a net loss of approximately $638,000, or $0.02 per basic and diluted share, compared to net income of $88,000, or $0.00 per basic and diluted share, for the same period in 2011. During the three months ended September 30, 2012 and 2011, the Company recorded a gain of $2.8 million and $2.3 million, respectively, related to the change in the fair value of the Company’s warrant liabilities. For the nine months ended September 30, 2012, the Company reported a net loss of approximately $15 million, or $0.38 per basic and diluted share, compared to $4.2 million, or $0.16 per basic and diluted share, in the same period last year. The net loss for the nine months ended September 30, 2012, includes a $5 million charge related to the change in the fair value of the Company’s warrant liabilities as compared to a $1.5 million gain in the prior year.

For the nine months ended September 30, 2012, the Company’s operating activities used $9.2 million compared to $4.6 million in the prior year, primarily to fund the Company’s R&D activities in connection with the Phase IIb trial of ICT-107, in which we increased the number of operational sites to 25 from 11 sites at December 31, 2011, as well as R&D activities in connection with ICT-121 and ICT-140 and general and administrative expenses. As of September 30, 2012, the Company had cash on-hand of $10 million. The September 30, 2012 cash balance does not reflect the net proceeds of approximately $19.3 million from the Company’s October 2012, underwritten public offering.

Commented John S. Yu, M.D., Interim Chief Executive Officer of ImmunoCellular:

“We continue to be pleased with our company’s progress, especially in advancing our development pipeline of cancer vaccines, led by ICT-107, which is anticipated to complete a Phase IIb trial at the end of 2013. Our plans to initiate the Phase I trial for ICT-121 in recurrent glioblastoma and to file an investigational new drug application (IND) for ICT-140 in ovarian cancer are on track. We are confident that with the additional funding we secured after the close of the third quarter, we have sufficient resources to continue to execute our business plan and prepare for next steps in our promising clinical programs. Our company’s virtual business model is enabling us to operate in an effective and capital-efficient manner, while benefiting from the expertise of talented pharmaceutical executives and the support of our highly engaged board of directors.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,928.20 -142.20 -0.79%
S&P 500 2,089.46 -25.03 -1.18%
NASDAQ 4,939.3270 -77.6020 -1.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs